Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms JH-XIII-05 |
Target |
Action degraders |
Mechanism IRAK1 degraders(Interleukin-1 receptor-associated kinase 1 degraders), IRAK4 degraders(Interleukin-1 receptor-associated kinase 4 degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-Cell Lymphoma | Preclinical | United States | 06 Dec 2024 | |
| Lymphoma | Preclinical | United States | 01 Jun 2024 |





